You are here
Report Explores Health Effects of Marijuana and Related Products
A new report from the National Academies of Sciences, Engineering, and Medicine offers a rigorous review of scientific research published since 1999 on what is known about the health impacts of cannabis and cannabis-derived products—such as marijuana and active chemical compounds known as cannabinoids—ranging from their therapeutic effects to their risks for causing certain cancers, diseases, mental health disorders, and injuries.
The committee that carried out the study and wrote the report considered more than 10,000 scientific abstracts to reach its nearly 100 conclusions. The committee also proposed ways to expand and improve the quality of cannabis research efforts, enhance data collection efforts to support the advancement of research, and address the current barriers to cannabis research.
“For years the landscape of marijuana use has been rapidly shifting as more and more states are legalizing cannabis for the treatment of medical conditions and recreational use,” said Marie McCormick, Chair of the committee; the Sumner and Esther Feldberg Professor of Maternal and Child Health at Harvard T.H. Chan School of Public Health; and Professor of Pediatrics at Harvard Medical School.
“This growing acceptance, accessibility, and use of cannabis and its derivatives have raised important public health concerns,” McCormick added. “Moreover, the lack of any aggregated knowledge of cannabis-related health effects has led to uncertainty about what, if any, are the harms or benefits from its use. We conducted an in-depth and broad review of the most recent research to establish firmly what the science says and to highlight areas that still need further examination. As laws and policies continue to change, research must also.”
Currently, cannabis is the most popular illicit drug in the United States, in terms of past-month users. Based on a recent nationwide survey, 22.2 million Americans ages 12 years and older reported using cannabis in the past 30 days. This survey also reports that 90% of adult cannabis users in the United States said their primary use was recreational, with about 10% reporting use solely for medical purposes. Around 36% reported mixed medical and recreational use. In addition, between 2002 and 2015, the percentage of past-month cannabis users in the U.S. population ages 12 years and older has increased steadily from 6.2% to 8.3%.
Some of the committee’s findings include:
One therapeutic use of cannabis and cannabinoids is to treat chronic pain in adults. The committee found evidence to support that patients who were treated with cannabis or cannabinoids were more likely to experience a significant reduction in pain symptoms. For adults with multiple sclerosis-related muscle spasms, there was substantial evidence that short-term use of certain “oral cannabinoids”—man-made, cannabinoid-based medications that are orally ingested—improved their reported symptoms. Furthermore, in adults with chemotherapy-induced nausea and vomiting, there was conclusive evidence that certain oral cannabinoids were effective in preventing and treating those ailments.
Regarding the link between marijuana and cancer, the committee found evidence that suggests smoking cannabis does not increase the risk for cancers often associated with tobacco use, such as lung and head and neck cancers. The committee also found limited evidence that cannabis use is associated with one subtype of testicular cancer and insufficient evidence that cannabis use by a mother or father during pregnancy leads to a greater risk of cancers in the child.
There is a lack of data on the effects of cannabis or cannabinoid-based therapeutics on the human immune system, as well as insufficient data to draw overarching conclusions concerning the effects of cannabis smoke or cannabinoids on immune competence, the committee stated. There is also insufficient evidence to support or refute a statistical association between cannabis or cannabinoid use and adverse effects on immune status in individuals with human immunodeficiency virus. Nevertheless, limited evidence suggests that regular exposure to cannabis smoke may have anti-inflammatory activity.
The evidence suggests that cannabis use is likely to increase the risk of developing schizophrenia, other psychoses, and social anxiety disorders, and to a lesser extent depression. Alternatively, in individuals with schizophrenia and other psychoses, a history of cannabis use may be linked to better performance on learning and memory tasks. Heavy cannabis users are more likely to report thoughts of suicide than nonusers, and in individuals with bipolar disorder, near-daily cannabis users show increased symptoms of the disorder than nonusers.
The committee found that learning, memory, and attention are impaired after immediate cannabis use. Limited evidence suggests impairments in cognitive domains of learning, memory, and attention in individuals who have stopped smoking cannabis. In addition, there is limited evidence to suggest that cannabis use is related to impairments in subsequent academic achievement and education as well as social relationships and social roles. Adolescence and young adulthood are when most youth begin to experiment with substances of abuse, including cannabis, and it is during these periods that the neural layers that underlie the development of cognition are most active. The committee also found limited evidence of an association between cannabis use and increased rates of unemployment and low income.
Challenges and Barriers in Research
In addition to recommending more research on the effects of cannabis and cannabinoid use, the committee emphasized several challenges and barriers in conducting such research. For instance, specific regulatory barriers, including the classification of cannabis as a Schedule I substance, impede the advancement of research. Researchers also often find it difficult to gain access to the quantity, quality, and type of cannabis product necessary to address specific research questions.
The full report is available for purchase or free download at: www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoid....
Source: National Academies of Sciences, Engineering, and Medicine; January 12, 2017.